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Abstract
Background: The behavioural impact of pharmacogenomics is untested. We tested two hypotheses concerning the
behavioural impact of informing smokers their oral dose of NRT is tailored to analysis of DNA.
Methods and Findings: We conducted an RCT with smokers in smoking cessation clinics (N=633). In combination with NRT
patch, participants were informed that their doses of oral NRT were based either on their mu-opioid receptor (OPRM1)
genotype, or their nicotine dependence questionnaire score (phenotype). The proportion of prescribed NRT consumed in
the first 28 days following quitting was not significantly different between groups: (68.5% of prescribed NRT consumed in
genotype vs 63.6%, phenotype group, difference = 5.0%, 95% CI 20.9,10.8, p=0.098). Motivation to make another quit
attempt among those (n = 331) not abstinent at six months was not significantly different between groups (p = 0.23).
Abstinence at 28 days was not different between groups (p=0.67); at six months was greater in genotype than phenotype
group (13.7% vs 7.9%, difference = 5.8%, 95% CI 1.0,10.7, p = 0.018).
Conclusions: Informing smokers their oral dose of NRT was tailored to genotype not phenotype had a small, statistically
non-significant effect on 28-day adherence to NRT. Among those still smoking at six months, there was no evidence that
saying NRT was tailored to genotype adversely affected motivation to make another quit attempt. Higher abstinence rate at
six months in the genotype arm requires investigation.
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Introduction
Background
Pharmacogenomics has the potential to improve health out-
comes in two key ways: first, by more effective prescribing, tailored
to genotype; and second, by increasing motivation to take
treatment. We present here the results of the first randomised
controlled trial assessing the behavioural impact of informing
smokers that their dose of medication is tailored to their genotype,
as opposed to non-genetic information.
Both the initiation and maintenance of smoking have been
reported as having high heritability [1,2,3]. There is also growing
evidence that some of the variability in responsiveness to smoking
cessation pharmacotherapy, such as nicotine replacement therapy
(NRT) or bupropion, is explained by genotype [4,5,6]. Genetic
tests are now available via the Internet (e.g. Respiragene (www.
synergenz.com)) which claim to identify the optimal pharmaco-
therapy for an individual wishing to stop smoking or to motivate
an individual to stop smoking but the impact of such testing has
not been evaluated.
This trial uses testing for the Asp40 variant in the mu-opiod
receptor (OPRM1) gene as its paradigm. During the design of
the trial, the mu-opioid receptor (OPRM1) gene was a promising
candidate which had been reported to be associated with
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follow-up among the group receiving the nicotine transdermal
patch was ,31% in those with one or more copies of the
Asp40 variant (present in about 25% of the population), and
,16% in those with two copies of the Asn40 variant. The rates
among the group receiving the nicotine nasal spray were ,15%
and ,13%, respectively. Therefore, Asp40 carriers appeared to
show double the short term quit-rates when using a form of
NRT with higher levels of replacement, compared with NRT
that results in lower levels of replacement. However, it should
be noted that the genotype 6 treatment interaction effect was
not statistically significant in this study, and subsequent studies
have failed to replicate this finding [8]. Nevertheless, for our
purposes, whether individuals’ genotype influences smoking
cessation is not directly relevant. The focus here is rather the
behavioural impact of communicating to smokers that their
medication has been tailored on a genetic basis. We therefore
chose the OPRM1 gene on the basis of evidence available at the
time of trial design, to establish proof-of-principle of commu-
nicating genetic tailoring of medication.
There are high expectations that DNA-based risk information
will motivate greater behaviour change than other types of
biomarker risk information [9,10,11]. There are two possible
mechanisms for such effects. First, information with high personal
salience, such as DNA-based risk information, has a greater
impact on attitude change than information with low personal
salience [12]. Second, perceiving a health problem to have
a genetic cause increases the perceived effectiveness of taking
medication to deal with the problem [13]. This has been
documented for depression, heart disease and stopping smoking
[14,15,16,17]. Given that perceived treatment effectiveness
predicts treatment use [18], tailoring treatment on the basis of
genetic testing has the potential to improve treatment outcomes by
increasing adherence. Higher use of NRT is associated with
a greater likelihood of smoking cessation [19,20].
In contrast to these positive effects, informing patients that their
prescription is tailored to their genotype may have negative effects
through engendering a sense of fatalism, which is associated with
perceiving a genetic cause to a health problem [21]. While
perceived control seems unaffected by the communication of
personalised genetic risk information [22], fatalism may be
induced in those who fail to change their behaviour following
such information. In the current context this could reduce
motivation to make a future quit attempt amongst those who fail
to quit.
Hypotheses. The trial tested two hypotheses:
Hypothesis I: Adherence to NRT is greater among smokers who
are informed their oral dose of NRT is tailored to an analysis of
DNA (genotype), rather than tailored to a nicotine dependence
questionnaire score (phenotype).
Hypothesis II: Among smokers who fail to quit at six months,
motivation to make another quit attempt is lower when informed
that their oral dose of NRT was tailored to genotype rather than
phenotype.
Methods
Ethical Approval
Ethical approval for the trial was granted (Hertfordshire 1
Research Ethics Committee, reference 06/Q0201/21) and the
local primary care trusts in Birmingham and Bristol gave approval
for the interventions. Additionally, the Medicine and Healthcare
Products Regulatory Authority gave approval (MHRA ref: 24570/
0002/001–0001).
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Design Overview
An open label, parallel group, randomised controlled trial of
NRT for smoking cessation in which participants were randomly
allocated on a 1:1 basis to one of two groups:
i. NRT oral dose tailored by DNA analysis, or
ii. NRT oral dose tailored by nicotine dependence score
We required a design which would result in a balance of gene
variants and nicotine dependence across groups and would
generate similar prescriptions of NRT in both groups, despite
the communicated basis of prescriptions (genotype or phenotype)
varying systematically by group. A design in which we would have
randomised the rationale given for the prescription, but held the
prescribed NRT constant (rather than it being tailored), was
rejected as it would have meant deceiving participants about the
true basis for their prescriptions.
Setting and Participants
The trial took place in the British National Health Service
(NHS) smoking cessation clinics in primary care. These provide
a combination of weekly behavioural support and pharmacother-
apy to assist smokers to quit. Participants were recruited from 29
primary care practices in two English cities, Birmingham and
Bristol.Patients smoking an average of at least 10 cigarettes a day
(including hand-rolled cigarettes), who wanted to quit and were 18
years or older, were eligible. Informed written consent was
obtained from all participants involved in the study.
Interventions
All participants were offered behavioural support and nicotine
replacement therapy by means of a skin patch, tailored for all
participants by phenotype (daily cigarettes smoked). The trial
interventions comprised the communication that the prescribed
dose for oral NRT treatment was based on either genotype
(intervention) or phenotype (comparison).
Support for behavioural change was based on withdrawal
orientated therapy [23] and was provided for all participants twice
prior to quit day and weekly thereafter until four weeks after
quitting and then once more eight weeks after quitting. All nurses
were trained to give behavioural support to NHS standards [24].
The support lasted 10–30 minutes, depending upon progress and
stage of the quit attempt. It was identical in both arms, except as
described below.
Nicotine replacement therapy (NRT) was offered to all
participants. Participants, regardless of group allocation, were
prescribed a nicotine patch dose based on daily cigarette
consumption. Smokers of 15 or more cigarettes daily were
prescribed 21 mg patches and those smoking 10–14 cigarettes
a day were prescribed 14 mg patches.
Participants were then prescribed a second oral ‘top-up’ NRT
with their choice of whether by gum, lozenge, sublingual tables or
inhalation spray. The dose was either 6 or 12 mg of absorbed
nicotine. A 2 mg gum leads to about 1 mg absorption, and
a 10 mg inhalator cartridge typically delivers about 3 mg. Thus
the prescribed doses were either 6 or 12 gum, lozenge, or
sublingual tablets, or 2 or 4 inhalator cartridges daily. Combina-
tion NRT (typically patch plus short-acting form as here), is
approximately 35% more effective than patch alone [25].
Behavioral Impact of Pharmacogenomics
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a) Genotype arm. The dose of oral NRT in this arm was
tailored to likelihood of responding to a higher dose as assessed by
gene variant. Participants’ blood or saliva samples were tested for
the OPRM1 Asn40Asp (A118G) variant (rs1799971) using
standard methods. Those who were homozygous for the Asn40
variant were prescribed a standard oral NRT dose of 6 mg a day.
Those who were heterozygous or homozygous for the Asp40
variant of the gene were prescribed a higher dose of oral NRT of
12 mg a day.
b) Phenotype arm. The prescribed dose of oral NRT in this
arm was determined using the Fagerstro ¨m Test for Nicotine
Dependence score [26] because there is evidence that more
dependent smokers benefit from higher doses [25]. Those scoring
less than eight were considered to have lower dependence and
were recommended to take a dose of oral NRT of 6 mg a day,
while those scoring eight or more were considered to have higher
nicotine dependency and were recommended to take a dose of
12 mg a day.
Communication of the basis for oral NRT. One day
prior to quit day, participants were given their NRT patches and
oral NRT and told the basis (genotype or phenotype) for the dose
of oral NRT by a research nurse who used a standard script that
was similar for both arms (see trial protocol [27]). This was
reinforced by a personalised booklet documenting the dose of
NRT to use daily and giving the reasons for that dose including
the physiological mechanisms by which taking their personalised
oral dose would increase their chances of stopping smoking. They
were also given an appointment card which summarised their
NRT doses and the basis for these (including whether their oral
dose was based on genotype (blood test) or phenotype (nicotine
dependence score), a weekly diary in which to record the NRT
consumed, and their first batches of NRT. The nurse reiterated
the rationale for the prescribed dose at each weekly clinic.
Recruitment and Follow-up Procedures
Potentially eligible smokers were identified from practice
registers and mailed a letter from their primary care physician
expressing concern about their smoking and offering assistance to
quit, with an invitation to participate in the trial. Interested
participants were screened for eligibility and then attended eight
clinic appointments, held weekly, with a research nurse. The quit
day occurred two weeks and a day after baseline. On the third
session, one day prior to quit day, the nurse revealed the
randomisation and told the participant the rationale for their dose.
Abstinence was recorded weekly and verified by exhaled carbon
monoxide (CO).
Adherence checks. The nurse assessed the NRT used from
the diary and a count of remaining NRT, and the NRT required
for the forthcoming week was dispensed.
Fidelity checks. The third clinic visits were audio-recorded
to assess fidelity to the communication protocol.
Non-attenders. When a participant did not attend a clinic,
the nurse made three attempts to contact him or her, after which it
was assumed that the participant had ceased trying to quit
smoking. Adherence was counted as zero for the remainder of the
four weeks unless he or she subsequently returned.
Longer term follow-up. All participants were contacted six
months following their quit date, either by telephone or by post.
Follow-up questionnaires were completed and, in those indicating
continued abstinence, a salivary sample was requested by post and
subsequently analysed for cotinine.
Outcomes and Follow-up Primary Outcomes
The primary outcome for hypothesis I was adherence, the
natural proximal behaviour for the intervention. While the trial
was not powered to detect a difference in long term behavioural
outcomes related to smoking, prolonged abstinence was measured
at six months post quit date.
Adherence to prescription of NRT over 28
days. Adherence to the prescription of NRT was assessed at
28 days following the quit date. It was defined as the proportion of
all NRT prescribed (in milligrams) that was consumed on each
day, averaged over this time period. Any over-consumption on
a day, relative to the amount prescribed, was defined as 100%
adherence. Consumption was measured using pill counts and
participants’ self-report, recorded in a daily diary. Quality of data
was categorised into ‘high’ and ‘lower’ quality. High quality data
consisted of i) adherence validated by both the self-report daily
diary and the pill count, or ii) data reporting the resumption of
smoking, whereby the participant informed the research team that
they had abandoned their quit attempt. ‘Lower’ quality data
consisted of all other permutations.
Motivation to make further quit attempts. This was
assessed in those who had returned to smoking at six months
follow-up. The measure comprised four items, with response
options provided on seven-point rating scales assessing likelihood
of a further quit attempt in the following four weeks. Mean values
on a composite scale (Cronbach’s alpha = 0.91) were positively
scored ranging from low (1) to high (7) motivation to quit in the
next four weeks.
Secondary Outcomes
Adherence to prescription of NRT over 7 days. It was
expected that the behavioural effects of the intervention would be
stronger in the first week of the quit attempt as fewer participants
would have resumed smoking. Adherence to prescription of NRT
was therefore assessed at 7 days, using the same approached as
described above for 28 days.
Abstinence from smoking. This was assessed using the
Russell standard procedures [28] counting participants lost to
follow up as being smokers and smoking status was verified
biochemically. At 28 days abstinence was defined as fewer than
five cigarettes in the past two weeks verified by CO,10ppm. At
six months, it was prolonged abstinence since the start of week 3,
with fewer than five cigarettes smoked and verified by
cotinine,15 ng/ml.
Additional Outcomes
Non-use of NRT. We report the proportion at 28 days who
had consumed no NRT during the trial.
Use of NRT beyond 28 days. At six months, we asked
participants whether their use of NRT had continued beyond the
28-day treatment period with responses coded as ‘yes’ or ‘no’.
Anxiety. At baseline, one week and six month follow-up,
anxiety was measured using the six-item, short-form of the state
scale of the Spielberger State-Trait Anxiety Inventory (STAI-6)
[29].
Sample Size
The detectable effect size was chosen to be 7.5% difference in
NRT consumption over the 28-day period of NRT prescription,
equivalent to a two-day difference. 630 participants provided
90% power using a two-sided unpaired t-test at the 5% level of
significance, allowing for 20% dropout. The variability in this
skewed outcome and the appropriateness of a t-test were
evaluated using a previous simulation of daily prescribed NRT
Behavioral Impact of Pharmacogenomics
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large enough to meet the assumptions required of a t-test to
compare mean adherence between study arms [30]. Clustering
was not allowed for in the analysis: the mean cluster size was
anticipated to be close to one [31] and was confirmed to be
1.05 participants per family.
Randomisation
Randomisation was stratified by cigarettes smoked per day (10–
14, 15+), FTND score (,8, 8–10), and four nurses. Within each
stratum, a randomisation sequence was computer generated using
random selected block sizes with a one-to-one allocation ratio.
Families were allocated as clusters to the same arm to avoid
contamination [31]. The trial statistician generated the sequences
and received the stratifier data and participant and family
identifier required to randomise participants, and participant date
of birth to confirm group allocation at trial closure. Allocations
were made in one central location, separate from trial co-
ordination, database, and participant enrolment.
Blinding
The randomisation sequence was revealed sequentially and
concealed from the trial team, nurses and participants.
However, after assignment to group, nurses, participants, and
the trial team were inevitably not blind to allocation. Nurses
were informed which dose and communication type they should
use before the participants arrived for visit 3 (one day prior to
quit date) and the rationale for the prescription was given
weekly to participants. Group allocation was concealed from the
research team collecting secondary outcome data on self-
reported smoking status.
Statistical Analysis
Intention-to-treat analyses were conducted using SPSS version
15. Adherence outcomes were analysed by comparing adherence
to NRT between the two arms by using an independent samples t-
test and estimating the 95% confidence interval for the between-
arm difference in mean NRT consumption. Motivation to make
another quit attempt was compared between arms in the subgroup
that were not abstinent at six months follow-up, using an
independent samples t-test.
Smoking abstinence was assessed by comparing the proportion
in each arm that were abstinent using a chi-squared test and
estimating the difference in proportions with the 95% confidence
interval.
Further details on the methods used in this trial are reported
elsewhere, in the trial protocol [27].
Results
Participant Flow
This is shown in Figure 1. Of 20,254 smokers identified, 19,415
did not respond.
Of the 839 who did respond, 206 were deemed ineligible,
declined to participate or failed to attend the first clinic
appointment required for trial recruitment. This resulted in 633
eligible patients who agreed to participate and who were
randomised (3.1%).
Recruitment
The overall period of recruitment and follow-up ran from June
2007 – September 2009.
Baseline Data
Baseline demographic characteristics of the two trial groups
were similar. Smoking characteristics were similar across groups,
including genotype distributions and NRT prescribed (Table 1).
Numbers Analysed
We analysed the primary endpoint for all 633 randomised
individuals using an intention-to-treat analysis, with missing data
regarded as representing zero adherence.
Outcomes (see Table 2)
Primary Outcomes
Adherence to prescription of NRT over 28 days. The
proportion of prescribed NRT consumed in the first 28 days
following quitting was not significantly different between groups:
(68.5% of prescribed NRT consumed in the genotype vs.
63.6%, in the phenotype group, difference = 5.0%, 95% CI
20.9,10.8, p=0.098), equivalent to 1.5 days or 1.4 mg per
day of extra adherence over the 28-day period. Adherence data
were classified as high quality for 68.1% of assessments. See
Figure 2.
Motivation to make further quit attempts. For this
analysis, the number included was 331 (165 in the genotype
arm and 166 in the phenotype arm). Of the 302 participants
not included, 167 were excluded as they self-reported abstinence
and 135 were lost to follow-up. Participants contacted who were
not abstinent at six months (n=331) showed similar moderate
levels of motivation to make another quit attempt in the next
month (mean 4.4 vs. 4.7; difference = 20.3, 95% CI 20.7,0.2,
p = 0.23). Differences between trial arms were small (0.3 points
on this composite scale with 1 to 7 range, 2.0 SD (and mid-
value 4.0)) and not statistically significant with a narrow
confidence interval.
Secondary Outcomes
Adherence to prescription of NRT over 7 days. Analysis
of adherence at seven days demonstrated a small effect, similar to
that observed over 28 days, which was statistically significant
(75.4% consumed vs 69.5%; difference = 5.8%, 95% CI 0.3,11.4,
p = 0.040).
Abstinence from smoking. Participants in the genotype
arm were significantly more likely to be abstinent at six months
(13.7% (43/315) vs. 7.9% (25/318); difference = 5.8%, 95%
CI 1.0,10.7, Relative Risk (RR) = 1.74 (95% CI 1.09,2.76), p
= 0.018) compared with those in the phenotype arm. This
analysis was based on biochemically validated non-smokers,
comprising 56.7% (68/120) of those participants who self-
reported 6-months abstinence: 61.4% (43/70) of those in the
genotype arm, and 50.0% (25/50) of those in the phenotype
arm. There was no significant difference between arms in
validated abstinence at 28 days (47.9% (151/315) vs. 46.2%
(147/318); difference = 1.7%, 95% CI: 26.1,9.5, RR=1.04
(95% CI 0.88,1.22), p = 0.67).
Additional Outcomes
Participants in the phenotype arm (16% (52/318)) were more
likely than those in the genotype arm (10% (32/315)) to take no
NRT: x
2(1) = 5.27, p =.022. This difference remained when
those who did not receive the intervention were removed from
the analysis (11% (34/318) vs 6% (19/315): x
2(1) = 4.48, p
=.034).
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report continuing use of NRT beyond the 28-day treatment period
(74.2% (190/256) vs.64.1% (152/237); x
2(1) = 5.89, p =.015).
Harms. Three serious adverse events were reported, all for
participants in the genotype arm (acute respiratory distress
syndrome with underlying pneumonia; right sided weakness
(possible minor stroke); leg fracture when hit by vehicle). None
was plausibly related to the prescribed NRT medication and in
all cases patients recovered without sequelae. At baseline, there
was no difference between groups in anxiety. Similarly, there
were no differences at one week or six month follow-up.
Fidelity to protocol. Sessions in which the differential basis
for tailoring of oral NRT was communicated were tape-recorded.
Assessment of a subsample of randomly selected recordings was
conducted (by CH) to assess the fidelity to the clinical protocol of
the intervention delivery. This was deemed acceptable in all cases,
with delivery of all key components.
Discussion
Principal Findings
We found a small, statistically non-significant effect on 28-day
adherence of communicating a tailoring of oral dose of NRT to
genotype rather than phenotype. This represented 1.5 days, or
1.4 mg per day difference between groups, in mean NRT
consumed over a 28 day period. No adverse effects on motivation
in those failing to quit were detected. Neither trial hypothesis was
supported.
Interpretation of Study Results
Taken together with the secondary outcomes, our results are
consistent with the intervention having a small positive effect upon
adherence amongst these participants. The evidence supporting
this effect is provided by the 95% confidence interval, with the
upper limit of 10.8% being consistent with there being a small
Figure 1. CONSORT flow diagram.
doi:10.1371/journal.pone.0035249.g001
Behavioral Impact of Pharmacogenomics
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35249Table 1. Demographic characteristics and baseline measures of smoking-related and other variables.
Genotype (n=315) Phenotype (n=318)
Demographic characteristics
Gender (%(n))
Male 46.0 (145) 45.3 (144)
Female 54.0 (170) 54.7 (174)
Age (m(sd)) 46.9 (13.4) 47.7 (13.2)
Ethnicity (%(n))
White 89.5 (282) 90.9 (289)
Black 3.5 (11) 1.9 (6)
Asian 2.8 (9) 1.3 (4)
Other 3.5 (11) 4.1 (13)
Missing 0.6 (2) 1.9 (6)
SES (%(n))
Group 1: most deprived 8.9 (28) 7.9 (25)
Group 2 20.3 (64) 22.6 (72)
Group 3 33.3 (105) 33.3 (106)
Group 4: least deprived 32.7 (103) 32.4 (103)
Missing 4.8 (15) 3.8 (12)
Weight in kg (m(sd)) 77.2 (17.7) 77.0 (18.2)
Baseline smoking variables
Fagerstro ¨m (m(sd)) 5.6 (2.1) 5.5 (2.3)
Fagerstro ¨m (%(n))
Score ,8 81.0 (255) 80.8 (257)
Score 8+ 19.0 (60) 19.2 (61)
Number of cigarettes smoked per day (m(sd)) 20.5 (8.7) 21.1 (8.5)
Number of cigarettes smoked per day (%(n))
10–14 cigarettes 19.4 (61) 21.4 (68)
15+ cigarettes 80.6 (254) 78.6 (250)
OPRM1 status (%(n))
Asn/Asn 81.0 (255) 75.8 (241)
Asn/Asp 18.7 (59) 21.7 (69)
Asp/Asp 0.3 (1) 0.3 (1)
Missing 0 2.2 (7)
Smoking – previous quit attempt (%(n))
Never tried to quit 28.3 (89) 22.7 (72)
#1 week or less 13.7 (43) 12.9 (41)
.1 week, #1 month 11.4 (36) 13.8 (44)
.1 month, #6 months 28.3 (89) 30.2 (96)
.6 months, #12 months 9.2 (29) 6.6 (21)
.1 year 8.3 (26) 13.2 (42)
Missing 1.0 (3) 0.6 (2)
Prescription received (%(n))
Standard patch & standard oral NRT (20 mg) 15.2 (48) 20.1 (64)
Standard patch & higher oral NRT (26 mg) 4.1 (13) 1.3 (4)
Higher patch & standard oral NRT (27 mg) 65.7 (207) 57.2 (182)
Higher patch & higher oral NRT (33 mg) 14.9 (47) 21.4 (68)
Total dose prescribed (mg) (m(sd)) 26.8 (3.6) 26.9 (4.2)
Other baseline variables
State anxiety (STAI-6) (m(sd)) 38.0 (11.9) 38.5 (13.6)
doi:10.1371/journal.pone.0035249.t001
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confidence interval is also consistent with there being a zero effect
of the intervention, but it is inconsistent with anything other than
a minute negative effect on smoking cessation. Further evidence to
support the intervention having a small effect upon adherence is
provided by the secondary outcome of NRT adherence at 7 days,
which is statistically significant, and a the biochemically validated
prolonged abstinence at 6 months. The higher abstinence
observed in the genotype group may in part have been due to
the higher proportion of participants in that group who initiated at
least some use of NRT as part of their quit attempt (see Figure 2)
as well as the higher proportion who reported using NRT beyond
the 28 day treatment period. These findings suggest that the
intervention may have had an effect both on initiation of the use of
NRT and treatment persistence. The factors that might help
interpret these observations will be explored in a separate paper.
This first empirical test of the behavioural impact of pharmaco-
genomicsreducestheuncertaintyaroundthepossiblesizeofimpact.
Theeffectonadherence,ifthereisone,islikelytobesmallerthanthe
twodaydifferenceinadherenceatonemonthonwhichwepowered
the study.
Overall, 11% of participants (68/633) were abstinent at six
months. The difference in abstinence between groups at six
months is larger than would be expected from the small observed
difference in adherence to NRT at 28 days and the negligible
difference in short-term abstinence. If the impact of the
intervention on abstinence is not explained by NRT adherence
over 28 days, there are a number of other explanations. First, this
may be a chance finding. Second, this may be due to bias in the
conduct of the study; however randomisation was effective, there
was no unequal attrition across groups and any bias might be
expected to be apparent during behavioural support and not after
it. Third, this may be a valid finding, not mediated by adherence
to NRT during the first 28 days of a quit attempt. Whilst we did
not assess adherence after 28 days in detail, during the six month
telephone follow-up we asked participants whether they had
consumed NRT beyond the initial treatment period, with more in
the genotype arm reporting such use than those in the phenotype
arm. This finding should, however, be considered with caution.
Table 2. Medication adherence, motivation to quit again and smoking abstinence.
Genotype n=315 Phenotype n=318
Difference (G – P) in mean or
proportion (95% CI) and p-value
Primary Outcomes
Proportion of all prescribed NRT consumed over 28 days (m(sd)) 68.5 (36.3) 63.6 (39.0) 5.0 (20.9, 10.8) p= 0.098
Motivation to make another quit attempt (m(sd)) 4.4 (2.0) 4.7 (2.0) 20.3 (2.7,.2) p = 0.228
Secondary Outcomes
Proportion of all prescribed NRT consumed over first 7 days (m(sd)) 75.4 (34.1) 69.5 (37.2) 5.8 (0.3, 11.4) p = 0.040
28-day prolonged abstinence, validated (%(n)) 47.9 (151) 46.2 (147) 1.7, (26.1, 9.5) p = 0.667
6-month prolonged abstinence, validated (%(n)) 13.7 (43) 7.9 (25) 5.8 (1.0, 10.7) p =0.018
doi:10.1371/journal.pone.0035249.t002
Figure 2. Distribution of adherence to NRT over 28 days after quit date by trial arm.
doi:10.1371/journal.pone.0035249.g002
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analysis was not specified prior to conducting the study. The
observed effect on long-term abstinence may also reflect impact of
the intervention on other smoking-related behaviours which we
did not assess. Further analyses of these data, modelling causal
effects of psychological and other variables collected during the
trial, may shed some light on this.
We found no effect on continuing intention to quit smoking
from informing participants that their oral NRT dose was tailored
to genotype rather than phenotype. In particular people in the
genotype arm who were not abstinent at six months were as likely
to plan a further quit attempt as those in the phenotype arm.
Despite the plausibility and frequently expressed concerns for such
an effect, these findings are consistent with other, related evidence
synthesised in a systematic review which provide no evidence to
suggest that communicating personalised genetic risk information
engenders feelings of fatalism [22]. The results of the current study
add to this by showing, we believe for the first time, that feelings of
fatalism are also not engendered by failure to change behaviour
following personalised genetic risk information.
Strengths and Limitations of the Study
The study has several strengths. First, it is novel, being the first
to test the behavioural impact of pharmacogenomic tailoring of
medication. Second, we used a robust design with evidence of
success in balancing the two groups for key confounders including
baseline smoking variables and genotype. Third, we powered for
a plausible and clinically important difference. Fourth, we used
objective measurement with biochemical verification of smoking
status, which strengthens the interpretation of smoking abstinence.
There are also limitations. The primary endpoint was not
smoking abstinence which would have required a larger trial.
Adherence was chosen as the endpoint as the impact on smoking
cessation of the intervention was predicted to work through
adherence to NRT. The measure of adherence was based in part
on self-report of medication use. Consumption was assessed using
‘pill’ counts as well as diary records and the practice nurse checked
for discrepancies at each clinic visit and reconciled them with
participants. We used more than one index of adherence to
increase reliability. While the measures used lack the precision of
some electronic devices, such devices cannot be used to measure
length of exposure to patches or gums. Regarding the second
hypothesis, we did not measure quitting behaviour beyond six
months to assess whether motivation to make a quit attempt in
those who were not abstinent reflected in actual behaviour.
Motivation is, however, a reasonable indicator of subsequent
behaviour [32].
The experimental design constrains the conclusions that can be
reached. The design that was ultimately chosen does not clearly
separate the relative influences of communication of the basis for
prescribing and dose tailoring. The most attractive experimental
design to investigate the effects of communication would have
required us to use the same dosing algorithm in both arms but to
randomise each arm to receive different information on the
method used to tailor the dose. Clearly this would have
necessitated deceiving participants and we regarded this as
unacceptable. We considered seeking informed consent to this
approach, but rejected it because of concerns that this might
undermine trust in the trial as a whole. The design is limited in two
further ways that may have produced a conservative estimate of
the intervention effect. First, all participants received a prescription
tailored to phenotype for transdermal NRT which may have
served to dilute the impact of the intervention. The design was
further limited by not including a group that received standard
care only, or a group that received no behavioural treatment i.e.
only tailored NRT prescriptions. Future studies might usefully
assess the impact of communicating treatments tailored by
genotype in different treatment contexts.
Generalisability
As expected, a minority of smokers (3.1%) who received an
invitation to join a study of smoking cessation did so. In the UK
around 5% of smokers a year use behavioural support and
medication provided by NHS clinics. That our uptake is similar
suggests that the results are likely to be generalisable to smokers
trying to stop smoking with support and medication. It was our
impression that people participated primarily to stop smoking
rather than to participate in research.
Implications for Clinicians and Policy Makers
The results of the current study suggest that communicating to
smokers that their NRT dose has been tailored by genotype is
unlikely to cause harm. The effects on adherence were small at
best, and the effects on abstinence and their mechanism, unclear.
If the observed effects on smoking cessation at six months are
replicated, however, genotype tailoring could contribute positively
at a population level to smoking cessation interventions. Any
possible contribution of genotype to tailored prescribing in
smoking cessation should not detract from the increasing evidence
for prescribing larger doses of NRT for more dependent smokers
[25]. Beyond smoking cessation, the current study is broadly
consistent with effects of DNA-based risk communication observed
across a range of health behaviours [33], suggesting that these
effects are likely to be small or non-existent, and not have the
aggregate behavioural impact that many anticipated.
Unanswered Questions and Future Research
Unanswered questions arising from these findings include: are
the effects on smoking abstinence at six months real and how are
they mediated, and, to what extent does the behavioural response
to the communication of tailoring of medication to genotype vary
by disease or service context?
Conclusion
This first empirical test of the behavioural impact of
pharmacogenomics suggests that the impact on adherence to
NRT may be small, at best. Further studies are warranted given
the design constraints and the potential for behavioural impact
with potential clinical significance. No adverse effect was detected
on motivation to start another quit attempt amongst those who
were not abstinent at six months. The unexpected higher rate of
abstinence at six months in the genotype arm needs further
investigation.
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